References
- Bigger JT Jr, Fleiss JL, Rolnitzky LM. Prevalence, characteristics, and significance of ventricular tachycardia detected by 24-hour continuous electrocardiographic recordings In the late hospital phase of acute myocardial infarction. Am J Cardiol 1986: 58(13): 1151–60
- Kostis JB, Byington R, Friedman LM, et al. Prognostic significance of ventricular ectopic activity in survivors of acute myocardial infarction. J Am Coll Cardiol 1987: 10(2): 231–42
- Furberg CD. Effect of antiarrhythmic drugs on mortality alter myocardial Infarction. Am J Cardiol 1983: 52(6): 32–6C
- Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985: 27(5): 335–71
- Bigger JT Jr. Definition of benign versus malignant ventricular arrhythmias: targets for treatment. Am J Cardiol 1983: 52(6): 47–54C
- The Cardiac Arrhythmia Pilot Study (CAPS) Investigators. The effect of encainide, flecainide, imipramine, and moricizine on ventricular arrhythmias occurring 6 to 60 days after myocardial infarction: results of a randomized, double-blind, multicenter trial. Am J Cardiol 1988: Apr
- Graboys TB, Lawn B, Podrid PJ, et al. Long-term survival of patients with malignant ventricular arrhythmia treated with antiarrhythmic drugs. Am J Cardiol 1982 50(3): 437–43
- Swerdlow CD, Winkle RA, Mason JW. Determinants of survival in patients with ventricular tachyarrhythmias. N Engl J Med 1983: 308(24): 1436–42
- Anderson JL, Bigger JT Jr, Laidlaw J, et al. Issues in the use of antiarrhythmic agents: focus on flecainide. Pract Cardiol 1987: 13(Jan): 108–34
- Vaughan Williams EM. A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol 1984: 24(4): 129–47
- Flecainide-Quinidine Study Group. Flecainide versus quinidine for treatment of chronic ventricular arrhythmias: a multicenter clinical trial. Circulation 1983: 67(5): 1117–23
- Roden DM, Woosley RL. Tocainide. N Engl J Med 1986: 315(1): 41–5
- Campbell RW. Mexiletine. N Engl J Med 1987: 316(1): 29–34
- Roden DM, Woosley RL. Flecainide. N Engl J Med 1986: 315(1): 36–41
- Harrison DC, Morganroth J, eds. A symposium: encainide. January 24–25, 1986. Phoenix. Am J Cardiol 1986: 58(5): 1–116C
- Mason JW. Amiodarone. N Engl J Med 1987: 316(8): 455–66
- Duff HJ, Roden D, Primm RK, et al. Mexiletine in the treatment of resistant ventricular arrhythmias: enhancement of efficacy and reduction of dose-related side effects by combination with quinidine. Circulation 1983: 67: 1124–8
- Duff HJ, Mitchell LB, Manyari D, et al. Mexiletine-quinidine combination: electrophysiologic correlates of a favorable antiarrhythmic interaction in humans. J Am Coll Cardiol 1987: 10(5): 1149–56
- Velebit V, Podrid P, Lown B, et al. Aggravation and provocation of ventricular arrhythmias by antiarrhythmic drugs. Circulation 1982: 65(5): 886–94
- Morganroth J, Anderson JL, Gentzkow GD. Classification by type of ventricular arrhythmia predicts frequency of adverse cardiac events from flecainide. J Am Coll Cardiol 1986: 8(3): 607–15
- Block PJ, Winkle RA. Hemodynamic effects of antiarrhythmic drugs. Am J Cardiol 1983: 52(6): 14–23C
- Podrid PJ, Schoeneberger A, Lown B. Congestive heart failure caused by oral disopyramide. N Engl J Med 1980: 302(11): 614–7
- De Paola AA, Horowitz LN, Morganroth J, et al. Influence of left ventricular dysfunction on flecainide therapy. J Am Coll Cardiol 1987: 9(1): 163–8
- Fogoros RN, Fiedler SB, Elson JJ. The automatic implantable cardioverter-defibrillator in drug-refractory ventricular tachyarrhythmias. Ann Intern Med 1987: 107(5): 635–41